NeuroSense Therapeutics Ltd. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
NeuroSense Therapeutics Ltd. (NRSN) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations of -$3.21 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations · last filed 2026-03-31
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 6 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 12 month |
|---|---|---|
| 2025-12-31 | -$3.21M 20-F · filed 2026-03-31 | |
| 2025-06-30 | -$2.71M 6-K · filed 2025-08-01 | |
| 2024-12-31 | $738.00K 20-F · filed 2026-03-31 | |
| 2024-06-30 | -$1.43M 6-K · filed 2025-08-01 | |
| 2023-12-31 | -$903.00K 20-F · filed 2026-03-31 | |
| 2023-06-30 | $3.55M 6-K · filed 2024-09-30 | |
| 2022-12-31 | -$7.52M 20-F · filed 2025-04-07 | |
| 2021-12-31 | $10.36M 6-K · filed 2024-06-17 |